The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-03

Study Completion Date

2016-09-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Exenatide is an incretin-like drug that has been approved for treatment of type 2 diabetes; it improves glycemia by increasing insulin and decreasing glucagon secretion by pancreatic islet cells and delaying gastric emptying. This randomized, placebo-controlled study is to evaluate whether exenatide over a 5 week period in non-diabetic obese subjects may lead to weight loss. To control for variability in individual response to weight loss treatment, this study will assess the role of exenatide in changing food intake and energy expenditure as possible sources of weight loss. This study will also evaluate the safety profile of exenatide in non-diabetic obese people. Additional assessments will evaluate changes in body fat and hormones involved in the sensations of hunger and fullness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET

NCT00747968

Type 2 Diabetes

COMPLETED PHASE2/PHASE3

Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function

NCT02584075

Coronary Endothelial Function

UNKNOWN PHASE4

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

NCT00974272

Type 2 Diabetes Mellitus Impaired Glucose Tolerance

COMPLETED PHASE4

Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy

NCT02129985

Type 2 Diabetes

UNKNOWN PHASE4

The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults

NCT00845559

Obesity Insulin Resistance Impaired Glucose Tolerance +1 more

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Obesity can lead to a number of health problems including diabetes, heart disease, stroke, low back pain, fatty liver disease, and osteoarthritis. The medical treatments currently available for obesity are limited. Exenatide is an injectable medication approved for treatment of type 2 diabetes that causes weight loss in some diabetic subjects. The reasons exenatide is thought to cause weight loss include decreased food intake, increased feelings of fullness and nausea. Because levels of a human gut hormone (glucagon like peptide 1) that is similar to exenatide have been shown to be related to resting energy expenditure, it is also possible that exenatide may have effects on a person s metabolism, a.k.a. energy expenditure, but any effect of exenatide on energy expenditure has yet to be evaluated. Even though exenatide is used to treat diabetes, administration of exenatide to non-diabetic lean individuals did not cause frankly low blood sugars.

The primary goal of this study is to investigate the way in which exenatide given twice a day to obese (BMI \>= 30 kg/m\^2) people without diabetes might lead to weight loss. Because response to weight loss treatment can be highly variable between individuals, we will look at the role of exenatide in changing food intake and energy expenditure as possible explanations for weight loss. We will also assess the safety profile of exenatide in non-diabetic obese people.

This study will involve the use of exenatide or placebo, determined randomly, in obese individuals without diabetes over a 5 week period. The primary measurements will include effects of exenatide on energy expenditure and food intake. We will also look at changes in body fat and the levels of hormones involved in the sensations of hunger and fullness. We will assess if any exenatide-induced changes can predict which individuals lose weight over the 5 weeks. The safety and side effects of exenatide in non-diabetic individuals during this time will also be determined. Findings from this study would help to determine how exenatide works to cause weight loss in people without diabetes, who might benefit most, and would help to improve understanding of why some people respond better to weight loss treatment than others.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Weight Loss Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exenatide

10 micrograms subcutaneously twice

Group Type ACTIVE_COMPARATOR

Byetta (exenatide)

Intervention Type DRUG

Exenatide is an injectable medication

Weight loss

Intervention Type BEHAVIORAL

Because response to weight loss

Placebo

Twice daily

Group Type PLACEBO_COMPARATOR

Metabolic Chamber

Intervention Type OTHER

The subject stays in the small room

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Byetta (exenatide)

Exenatide is an injectable medication

Intervention Type DRUG

Weight loss

Because response to weight loss

Intervention Type BEHAVIORAL

Metabolic Chamber

The subject stays in the small room

Intervention Type OTHER

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Premenopausal women and men \< 55 years of age
* BMI \>30 kg/m(2)
* Expressed desire for weight loss
* Stable weight (variation \< 2.3 kg within past 6 months)
* Ability to provide informed consent
* Ability to follow verbal and written instructions
* Nonsmoker
* Ability to commute to study site on a regular basis for short outpatient visits over 5 weeks
* For females, use of a medically approved form of contraception. For oral contraceptives, subjects will need to be on an established dose for at least 3 months to ensure stable weight and will be asked not to switch contraceptive methods during study participation.

Exclusion Criteria

* Age \< 18 years
* Use of other medications to treat obesity including medications obtained over the counter or internet, orlistat (Xenical, Alli), sibutramine (Meridia), topiramate (with or without phentermine (Qsymia), phentermine (Adipex P) or lorcaserin (Belviq) within the past 6 months
* History of an eating disorder including anorexia or bulimia
* History of surgery for the treatment of obesity (gastric banding, gastric bypass)
* Diagnosis of type 1 or type 2 diabetes mellitus according to American Diabetes Association guidelines
* Previous exposure to exenatide
* Uncontrolled hypertension as defined by a blood pressure of 150/90 on two or more occasions or use of antihypertensive medications which may affect energy expenditure including alpha blockers, beta blockers, angiotensin receptor blockers or inhibitors of angiotensin converting enzyme
* Current use of tobacco products, marijuana, amphetamines, cocaine or intravenous drug use
* Chronic ethanol use (\> 3 drinks /day)
* Endocrine disorders including hypo or hyperthyroidism (including subclinical disease), Cushing s disease, growth hormone deficiency or other pituitary diseases
* History of pancreatitis
* Personal or family history of multiple endocrine neoplasia (MEN)-2 or medullary thyroid cancer
* History of unresolved gallstones
* Hyperamylasemia
* Fasting triglyceride level greater than or equal to 500
* Gastroparesis
* Inflammatory bowel disease or malabsorption disorders
* Malignancy treated with chemotherapy or radiation within the past 5 years
* Current clinical depression, diagnosis of psychosis or recent use of psychotropic medication
* Pregnancy within past 6 months
* Breastfeeding
* Failure to use medically approved contraceptive methods if subject is female
* Liver function abnormalities (transaminases greater than twice normal)
* Renal insufficiency (creatinine clearance \< 50 ml/min)
* History of chronic infection including tuberculosis, coccidiomycoses, lyme disease or HIV infection
* Pulmonary disorders, including chronic obstructive pulmonary disease, which would limit ability to follow the protocol (investigator judgment)
* Cardiovascular disease including history of myocardial infarction, unstable angina or heart failure
* Central nervous system disease, including history of cerebrovascular accidents, dementia, and neurodegenerative disorders
* Weight \<450 pounds (maximum weight of the DXA machine as per manufacturer s manual)
* Sensitivity to exenatide or any inert components in its formulation
* Sensitivity to acetaminophen
* Conditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the investigators

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes